(Q39882407)

15 September 2017

Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells (English)

1 reference

ubiquitin-proteasome system

15 September 2017

0 references

M Verdoes

6

0 references

author name string

T Rückrich

1

1 reference

15 September 2017

M Kraus

2

1 reference

15 September 2017

J Gogel

3

1 reference

15 September 2017

A Beck

4

1 reference

15 September 2017

H Ovaa

5

1 reference

15 September 2017

H S Overkleeft

7

1 reference

15 September 2017

H Kalbacher

8

1 reference

15 September 2017

C Driessen

9

1 reference

15 September 2017

19 February 2009

1 reference

15 September 2017

1 reference

15 September 2017

23

1 reference

15 September 2017

6

1 reference

15 September 2017

1098-1105

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2009.8

15 September 2017

0 references

cites work

The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

The ultimate nanoscale mincer: assembly, structure and active sites of the 20S proteasome core.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

7 January 2021

The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

7 January 2021

Proteasome inhibitors in cancer therapy: lessons from the first decade

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

7 January 2021

Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

7 January 2021

https://api.crossref.org/works/10.1038%2FLEU.2009.8

1 reference

7 January 2021

Mechanism and function of deubiquitinating enzymes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

7 January 2021

Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

7 January 2021

ERAD: the long road to destruction

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

7 January 2021

The unfolded protein response: a stress signaling pathway critical for health and disease.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

7 January 2021

Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Abeta-induced cell death

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

7 January 2021

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

7 January 2021

A proteolytic system that compensates for loss of proteasome function

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

7 January 2021

Cells adapted to the proteasome inhibitor 4-hydroxy- 5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

7 January 2021

Lysosomal cysteine proteases: facts and opportunities

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

7 January 2021

Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

7 January 2021

A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

7 January 2021

Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

7 January 2021

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

7 January 2021

Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

7 January 2021

Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

7 January 2021

Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

7 January 2021

Integration of the ubiquitin-proteasome pathway with a cytosolic oligopeptidase activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

7 January 2021

Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.8

7 January 2021

Identifiers

DOI

10.1038/LEU.2009.8

1 reference

15 September 2017

1 reference